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Abstract
So far, there are no means of identifying rheumatoid arthritis (RA) patients who will fail to respond to tumour necrosis factor
blocking agents (anti-TNF), prior to treatment. We set out to validate eight previously reported gene expression signatures
predicting therapy outcome. Genome-wide expression profiling using Affymetrix GeneChip Exon 1.0 ST arrays was
performed on RNA isolated from whole blood of 42 RA patients starting treatment with infliximab or adalimumab. Clinical
response according to EULAR criteria was determined at week 14 of therapy. Genes that have been reported to be
associated with anti-TNF treatment were extracted from our dataset. K-means partition clustering was performed to assess
the predictive value of the gene-sets. We performed a hypothesis-driven analysis of the dataset using eight existing gene
sets predictive of anti-TNF treatment outcome. The set that performed best reached a sensitivity of 71% and a specificity of
61%, for classifying the patients in the current study. We successfully validated one of eight previously reported predictive
expression profile. This replicated expression signature is a good starting point for developing a prediction model for anti-
TNF treatment outcome that can be used in a daily clinical setting. Our results confirm that gene expression profiling prior
to treatment is a useful tool to predict anti-TNF (non) response.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease,
which predominantly involves synovial joints and affects up to 1%
of the world’s population [1]. Tumour necrosis factor (TNF)
neutralization is one of the most effective therapeutic strategies in
RA. Nonetheless, this approach is not universally effective and
approximately 30% of patients treated with TNF blocking agents
fail to achieve or maintain clinical improvement [2]. The
combination of prolonged high disease activity, high costs and
risk for adverse effects in these non-responding patients has driven
the search for predictive markers – including genetic markers –
that are able to predict treatment outcome. Insight into the
genetics of anti-TNF therapy may facilitate the choice for the most
suitable therapy for an individual patient regarding efficacy and
safety, thus leading to more individualized treatment in daily
clinical practice [3].
In recent years, genome-wide gene expression analysis using
microarrays has become a key component in unravelling the
underlying transcriptional regulation of various complex diseases
[4-7]. Gene expression profiling studies in patients with RA have
not only revealed genes associated with the disease itself but also
identified molecularly distinct subgroups of RA patients [8-11].
Gene expression microarray technology has also shown to be able
to assist in identifying genes which are involved in treatment
response or adverse events associated with therapy [12-16]. To
date, several studies used genome-wide gene expression analysis to
identify gene expression signatures predicting the response to anti-
TNF treatment in patients with RA [8,17–28]. Lequerre ´ and co-
workers investigated peripheral blood mononuclear cell (PBMC)
derived RNAs from 13 RA patients treated with infliximab by the
use of a custom made microarray covering 10,000 non-redundant
human cDNAs. Expression levels prior to treatment initiation of
41 mRNAs were identified that perfectly separated subsequent
responders (n=6) from subsequent non-responders (n=7) to
infliximab. Validation in 20 other patients reduced the set to 20
transcripts which classify anti-TNF responders and non-respond-
ers with a sensitivity of 90% and a specificity of 70%. Further
reduction of the transcript set to only 8 transcripts changed
sensitivity to 80% and specificity to 100% [19]. More recently,
Julia et al. (44 patients) and Tanino et al. (42 patients) reported,
using white blood cells, an eight-gene and a ten-gene expression
signature predictive for anti-TNF response, respectively [22,23].
Stu ¨hlmuller and coworkers reported gene sets consisting of 82, 11
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genes in these sets (CD11c) could discriminate responders from
non-responders with a sensitivity of 100% and a specificity of
91.7%. Koczan and co-workers analyzed RNA extracted from
PBMCs three days after treatment initiation of 19 RA patients
treated with etanercept. Forty-two differentially expressed genes
were examined for their ability to discriminate between anti-TNF
responders and non-responders, reaching prediction accuracies of
95% [18].
Similar studies have been performed using arthroscopic biopsies
as RNA source. Lindberg et al. examining 10 RA patients, revealed
279 genes significantly differentially expressed in responders and
non-responders to infliximab [17]. Badot et al. analyzed 25 patients
an identified an expression signature of 439 genes to be associated
with poor response to anti-TNF therapy [24]. A large study
including biopsies of 65 patients could not identify an expression
profile predictive of treatment outcome [25].
Other studies used expression profiling to get more insight into
the mechanisms underlying the action of anti-TNF [20,21,27].
They suggest that responders to treatment are characterized by a
higher expression of inflammatory genes in synovial tissue [20]
and that the increased expression of inflammatory genes in
responders normalizes faster than in non-responders [21]. Baarsen
and colleagues showed that TNF treatment resulted in downreg-
ulation of genes in diverse immune related pathways including
inflammation, angiogenesis, B- and T-cell activation [26]. In a
second study they suggest that patients not responding to anti-
TNF treatment show an increase in expression of type I interferon
response genes [27].
Despite these promising results, the genes identified in each
study show little overlap. This can partly be caused by the high
false positive rate associated with multiple testing in a limited
sample, thus necessitating validation in separate cohorts. In this
report we used gene expression profiling on whole blood from 42
RA patients treated with the monoclonal anti-TNF antibodies
infliximab or adalimumab to validate previously reported gene
expression signatures [19,21–23,28] for their predictive value in
our independent cohort of RA patients treated with anti-TNF.
Results
Table 1 shows patients’ characteristics, mean disease activity
(DAS28) at baseline and DAS28 improvement 14 weeks after
treatment start. In total 42 RA patients treated with anti-TNF
were included in the study. According to the EULAR definition of
response [29], 18 patients in our sample responded well to anti-
TNF treatment and 24 patients showed no response to the
treatment. Twenty-seven patients were treated with infliximab, 15
were treated with adalimumab. No differences in patient
characteristics were observed between the responder and non-
responder groups except for DAS28 improvement after 14 weeks
of treatment. No differences in WBC numbers (lymphocytes,
neutrophils, eosinophils, basophils and monocytes) were observed
between the responder and non-responder group (data not shown).
Expression profiling on whole blood from these 42 RA patients
was performed to generate a whole-genome expression dataset.
We used this set to validate data from five previously published
studies by extracting the expression levels observed for the genes
reported by them from our dataset [19,21–23,28]. In total eight
transcript sets from the studies were linked to the expression values
of our 42 RA patients followed by K-mean clustering (Figure 1).
After clustering, the sensitivity and specificity for each of these
transcripts was calculated (Table 2). The best result was obtained
by the 20 genes transcript set of Lequerre ´ et al. This set was able to
classify our patients as anti-TNF responders and non-responders
with a sensitivity of 71% and a specificity of 61% (Figure 1A).
Although the other transcript sets also reached reasonable
sensitivities (ranging from 92% to 67%), the specificities were
low (ranging from 56% to 17%) (Table 2). Next, we performed an
exploratory genome-wide analysis of the data and identified 113
genes that, at baseline, were significantly differentially expressed in
responders and non-responders to TNF blockade by monoclonal
antibodies (Table S1).
Discussion
In this study we used genome-wide expression profiling to
validate eight previously reported gene expression signatures
predicting anti-TNF therapy outcome. To our knowledge, this is
the first study in which previously reported expression signatures
for anti-TNF response are re-investigated in an independent
patient cohort. This analysis was based on whole transcriptome
profiling prior to the first anti-TNF administration.
The expression profiles identified in different studies are often
not consistent with each other and different gene sets have been
reported to distinguish between responders and non-responders
[17-19,21-28,30,31]. One reason for the differences between
studies might be the limited sample sizes and the high rate of false
Table 1. Baseline characteristics, disease activity at baseline and DAS28 improvement for responders and non-responders to
anti-TNF treatment.
Responders Non-responders P-value
N (baseline and 14 weeks follow-up) 18 (43%) 24 (57%) NS
Female gender 16 (89%) 14 (58%) NS
Age (mean6SD) 58614.2 57613.6 NS
RF positivity 13 (72%) 19 (79%) NS
Adalimumab 4 (27%) 11 (52%) NS
Infliximab 14 (73%) 13 (48%) NS
MTX-comedication 18 (100%) 24 (100%) NS
DAS28 baseline (mean6SD) 5.361.0 4.861.5 NS
DAS28 decrease after 14 weeks of anti-TNF therapy (mean6SD) 2.060.8 0.161.0 ,0.0001
Results are number (percentage) or mean (SD). Percentages are expressed in relation to the total number of patients for each response group (except for the total
number of patients). P-value indicates a significant difference between the two response groups NS: not significant.
doi:10.1371/journal.pone.0033199.t001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33199Figure 1. Cluster analysis for the reported transcript sets. K-means cluster analysis based upon the transcript sets reported by (A) Lequerre ´ (20
genes) (B) Stuhlmuller (11 genes) (C) Stuhlmuller (82 genes) (D) Lequerre ´ (8 genes) (E) Sekiguchi (18 genes) (F) Julia (8 genes) (G) Stuhlmuller (3 genes)
and (H) Tanino (8 genes). The previously published transcript sets were linked to the expression values of 42 RA patients treated with anti-TNF in our
study. The two clusters were identified as the non-responder (1) and responder (2) clusters. Profiles are ranked according the results obtained after
clustering, in which profile A showed the best results.N=responder; #=non-responder.
doi:10.1371/journal.pone.0033199.g001
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inconsistent results might be differences in tissues used for analysis
(synovial biopsies, PBMCs, whole blood), RNA isolation and
analyses at different time points, differences in types and doses of
anti-TNF medication, differences in response criteria (ACR,
EULAR or DAS28 change), differences in techniques (array
platforms, q-PCR methods), differences in patient clinical
characteristics (disease activity, gender) and differences in patient
ethnicity (Caucasian, Asian). Despite the differences observed
between the studies it turns out to be possible to obtain a
reasonably good classification of anti-TNF responders and non-
responders for one of the eight previously described candidate
gene expression profiles. One transcript set (20 genes) from the
study of Lequerre ´ et al. [19] was validated with a sensitivity of 71%
and specificity of 61%. This 20 genes profile results in a relatively
good sensitivity and specificity in our data set, even in a different
type of material (whole blood versus PBMCs). However, we failed
to validate seven other previously described transcript sets.
Though these results can be viewed as a first step towards a
diagnostic test, a critical remark is in place. No moderate
responders were included in this cohort. Before such an expression
profiling test can be implemented in the clinic, validation of these
expression signatures in a larger cohort, consisting of good,
moderate and non-responders, is needed. Also the obtained
sensitivity of 71% and specificity of 61% are not high enough for
daily clinical practice. However, the sensitivity and specificity of
the tests might be further enhanced by including other types of
biomarkers, like genetic polymorphisms, and/or clinical charac-
teristics.
The current analysis should be viewed in the light of some
strengths and limitations. A relative strength of our study is the
sample size. Our study investigated 42 well characterized patients.
To our knowledge, it is for the first time that an expression
profiling dataset concerning anti-TNF (non-)response is used to
validate other, previously reported expression signatures for
predicting anti-TNF response. This leads to a more evidence-
based and better argued conclusion in favor of expression profiling
as a tool for predicting anti-TNF response then the results from
one single experiment. A limitation of the study is given by the fact
that RA is a very heterogeneous disease. Individual patient
characteristics like RF, DAS28, CRP, disease duration, disease
onset, age, co-medication, joint erosions, smoking and Health
Assessment Questionnaire (HAQ) will always be slightly different
between patients, which makes it very difficult to select two
homogeneous patient groups. This will most certainly limit the
power to detect gene expression differences between anti-TNF
responders and non-responders in diverse patient cohorts.
To conclude, this study successfully validated an earlier reported
gene expression profile predictive of anti-TNF treatment outcome.
Before this set can be used in clinical practice the predictive value
should be increased by adding additional predictors of anti-TNF
treatment outcome. However the validated gene-expression profile
can be viewed as a starting point to construct a prediction model
for anti-TNF treatment outcome.
Materials and Methods
Ethics statement
The ‘‘Commissie Mensgebonden Onderzoek (CMO) Regio
Arnhem Nijmegen’’ of the Radboud University Nijmegen Medical
Centre approved the study (CMO number 2004/014). All patients
had provided written informed consent prior to participation in
the study. All clinical investigation were conducted according to
the principles expressed in the Declaration of Helsinki.
Patients
All patients had RA according to the 1987 revised American
College of Rheumatology (ACR) criteria [32] and attended the
Departments of Rheumatology of the Radboud University
Nijmegen Medical Centre or the St. Maartenskliniek in Nijmegen.
The patients selected for the current study all participate in the
Dutch Rheumatoid Arthritis Monitoring (DREAM) registry (www.
dreamregistry.nl). The latter collects detailed clinical information
and treatment outcome of patients who start their first course of a
TNF-blocking agent according to the Dutch recommendations
(Disease Activity Score 28 (DAS28).3.2 and previous failure on at
least two disease-modifying antirheumatic drugs (DMARDs), one
of which has to be methotrexate (MTX)) [33] Response to TNF
neutralization was assessed at week 14 according to the EULAR
criteria [29]. Consecutive patients enrolled in the DREAM
registry between 2004 and 2008 were included in this study.
Only good responders and non-responders at 14 weeks based on
the EULAR response criteria were selected for expression
analyses. Patients with a moderate response were excluded. This
resulted in forty-two patients (18 good responders and 24 non-
responders) that were included in the study (Table 1), representing
the extremes of a total of 92 patients. Power calculations showed
that this sample of 42 patients had a power of 80% to detect a
minimal fold change of two with an alpha of 0.0000027.
Responders and non-responders were frequency-matched for
gender, age, RF-positivity and use of MTX. Blood was sampled
prior to treatment start (infliximab or adalimumab).
Molecular analyses
All molecular analyses were performed in a CCKL (Coo ¨rdinatie
Commissie ter bevordering van de Kwaliteitsbeheersing van het
Laboratoriumonderzoek) -accredited laboratory at the Depart-
ment of Human Genetics at the Radboud University Nijmegen
Medical Centre in Nijmegen. RNA was isolated from whole blood
within 0.5 hours after venapuncture, using the RNeasy midi kit
according to the manufacturer’s protocol (Qiagen Benelux B.V.
Venlo, The Netherlands). To remove residual traces of genomic
DNA, the RNA was treated with DNase I (Invitrogen, Leek, The
Netherlands) while bound to the RNeasy column. Quality and
quantity of the purified RNA was controlled using a NanoDrop
spectrophotometer (Nanodrop technologies, Montchanin, DE,
USA). RNA integrity was investigated by using the 2100
Bioanalyser (Agilent technologies, Philadelphia, PA, USA). RNA
Table 2. Sensitivity and specificity for each transcript set.
Study Reference Sensitivity (%) Specificity (%)
Lequerre ´ (20 genes) [19] 71 61
Stuhlmuller (11 genes) [28] 79 56
Stuhlmuller (82 genes) [28] 67 56
Lequerre ´ (8 genes) [19] 71 28
Sekiguchi (18 genes) [21] 71 28
Julia (8 genes) [23] 92 17
Stuhlmuller (3 genes) [28] 71 17
Tanio (8 genes) [22] 67 33
Eight previously published transcript sets were linked to the expression values
of 42 RA patients treated with anti-TNF in this study. After k-means cluster
analysis the sensitivity and specificity were calculated
doi:10.1371/journal.pone.0033199.t002
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electrophoresis.
Gene expression profiling was performed using Affymetrix 1.0
Human Exon ST arrays, representing all known genes (17881)
(Affymetrix Inc., Santa Clara, CA, USA) according to the
manufacturer’s instructions. The Affymetrix GeneChip Whole
Transcript Sense Target Labeling Assay was used to generate
amplified and biotinylated sense-strands DNA targets from the
entire expressed genome (2.0 mg of total RNA). Arrays were
hybridized by rotating them at 60 rpm in the Affymetrix
GeneChip hybridization oven at 45uC for 17 hours. After
hybridization, the arrays were washed in the Affymetrix GeneChip
Fluidics station FS 450. Arrays were scanned using the Affymetrix
GeneChip scanner 3000 7G system.
Data extraction
For quality control, the Affymetrix CEL-files were first imported
into Affymetrix Expression Console version 1.1 where control
probes were extracted and normalized using the default RMA
algorithm. The Area Under the Curve (AUC) of the Receiver
Operator Characteristic was calculated using the positive and
negative control probes. All arrays had an AUC score above the
empirically defined threshold of 0.85 indicating a good separation
of the positive controls from the negative controls. Pearson
correlation between arrays showed no outliers.
Subsequently, the CEL-files were imported into PartekH
(PartekH Genomic Suite software, version 6.4 Copyright  2008
Partek Inc., St. Louis, MO, USA) where only core probe sets were
extracted and normalized using the RMA algorithm with GC
background correction. Core transcript summaries were calculated
using the mean intensities of the corresponding probe sets,
representing the quantitative expression levels of all genes.
Expression data is generated according the MIAME guidelines
and is available through the GEO (Gene Expression Omnibus)
database (http://www.ncbi.nlm.nih.gov/geo), accession number
GSE33377. Genes that showed significantly differential expression
in responders and non-responders to TNF blockade by monoclo-
nal antibodies are presented in Table S1.
Validation of previously reported expression signatures
Using the PubMed database (accessed August 2011), we identified
a total of fourteen studies that used gene expression profiling to
predicttreatment outcome [17-28,31,34]. Nine studies were excluded
from validation as they analyzed gene expression levels after
treatment initiation [18,26,27,34] or used different starting material
(arthroscopic biopsies) [17,20,24,25,31]. The transcript sets from the
other studies[19,21-23,28] were included for validation in our patient
cohortbecausetheymatchedourexperimentalsetupinthefollowing
aspects: 1) all studies present transcript sets that are able to distinguish
between responders and non-responders based upon analyses at
baseline (before treatment start) and 2) the studies used blood cells as
starting material. The published transcript sets were linked to the
corresponding quantitative expression values obtained in our
analyses. K-means partition clustering was performed using Pearson
dissimilarity as a distance measure. The number of partition clusters
was set to two (non-responder and responder). The true positive and
true negative responses values were calculated. Sensitivity was
calculated by the following formula: true positives (true anti-TNF
non-responders identified as non-responders)/true positives+false
negatives (true non-responders identified as responders). Specificity
was calculated by the formula: true negatives (true responders
identified as responders)/true negatives+false positives (true respond-
ers identified as non-responders).
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